Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT05593185 is registered in ClinicalTrials.gov with Sellas Life Sciences Group as lead sponsor.

NCT NCT05593185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05593185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Lead sponsor
Sellas Life Sciences Group
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndromes